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Cyanobacteria are rich source of array of bioactive compounds. The present study
reports a novel antibacterial bioactive compound purified from cyanobacterium Nostoc
sp. MGL001 using various chromatographic techniques viz. thin layer chromatography
(TLC) and high performance liquid chromatography (HPLC). Further characterization
was done using electrospray ionization mass spectroscopy (ESIMS) and nuclear
magnetic resonance (NMR) and predicted structure of bioactive compound was
9-Ethyliminomethyl-12-(morpholin - 4 - ylmethoxy) -5, 8, 13, 16–tetraaza–hexacene - 2,
3 dicarboxylic acid (EMTAHDCA). Structure of EMTAHDCA clearly indicated that it is a
novel compound that was not reported in literature or natural product database. The
compound exhibited growth inhibiting effects mainly against the gram negative bacterial
strains and produced maximum zone of inhibition at 150 µg/mL concentration. The
compound was evaluated through in silico studies for its ability to bind 30S ribosomal
fragment (PDB ID: 1YRJ, 1MWL, 1J7T, and 1LC4) andOmpF porin protein (4GCP, 4GCQ,
and 4GCS) which are the common targets of various antibiotic drugs. Comparative
molecular docking study revealed that EMTAHDCA has strong binding affinity for these
selected targets in comparison to a number of most commonly used antibiotics. The
ability of EMTAHDCA to bind the active sites on the proteins and 30S ribosomal
fragments where the antibiotic drugs generally bind indicated that it is functionally similar
to the commercially available drugs.
Keywords: Nostoc sp. MGL001, novel bioactive compound, antibacterial agent, molecular docking, RNA
fragments, OmpF porin protein
INTRODUCTION
High proportion of drug resistance in bacterial pathogens indicated loss of efficacy of conventional
antibiotics as only one third of the diseases could be cured by currently available drugs (Karchmer,
2004; Reynolds et al., 2004; Paterson, 2006). Thus, screening of new biologically active compounds
are major thrust area at the present moment (Lahlou, 2013). To date, modern scientific advances
in drug discovery could not enable the pace of newer drug development because of very little
exploration of natural resources especially microbial metabolites (Cragg and Newman, 2013).
Actinomycetes, fungi, unicellular bacteria along with cyanobacteria contributed about 45, 38,
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and 17%, respectively, in producing bioactive metabolites (Berdy,
2005; El-Elimat et al., 2012). Of these organisms, cyanobacteria
are photoautotrophic in nature and can grow in presence of
small amount of nutrients (Bullerjahn and Post, 2014; Dias
et al., 2015). Due to these reasons, utilization of cyanobacteria in
scientific studies will be a cost effective approach. Cyanobacteria
constitute a rich source of unprecedented novel biologically
active metabolites (Singh et al., 2005; Sivonen and Börner,
2008; Prasanna et al., 2010), such as peptides, macrolides,
phenolic dilactones, polyketides, and alkaloids each of which
originate from different pathway and show a broad spectrum of
biological activities (Namikoshi and Rinehardt, 1996; Clardy and
Walsh, 2004; Kim and Lee, 2006). Estimate proclaim regarding
bioactive compounds in fresh water cyanobacteria shown to
exhibit antimicrobial, antifungal, antiviral, antitumor, anticancer,
and other pharmacological activities (Gul and Hamam, 2005;
Mayer and Hamann, 2005; Singh et al., 2005). Extensive
screening programme of cyanobacterial bioactive compounds
for antibiotics, pharmaceutical and agricultural application has
received considerable attention during the past few decades
(Patterson et al., 1994; Khairy and El-Kassas, 2010; Kumar et al.,
2010).
Among the cyanobacterial genera screened, Nostoc sp. are
distributed throughout tropical and subtropical regions and
proved as prodigious procedure of secondary metabolites. Genus
Nostoc is highly diversified and reported from various terrestrial
and aquatic habitats, and also able to form stable cyanobiont in
various symbiosis (Dodds et al., 1995). Nostoc species attracted
much attention as number of secondary metabolites were
isolated, examined and found to have antiviral and antitumor
properties (Dembitsky and Rezanka, 2005). Novel antimitotic
compound namely Nostodione A has been reported from Nostoc
commune (Kobayashi et al., 1994). Nostoc commune produced
novel extracellular diterpenoid having antibacterial activity (Jaki
et al., 1999). Potent antitumor agent and antifungal peptolides
viz. Cryptophycins which is a cyclic depsipeptides isolated from
Nostoc sp. showing excellent activity against broad spectrum of
drug sensitive and drug resistant solid tumors, implanted in mice
(Trimurtulu et al., 1994). An antiviral compound Cyanovirin-
N has been isolated from Nostoc ellipsosporum. Freshwater
Nostoc spongiaeforme produced Nostocine A exhibiting adverse
effect on growth of microorganisms, algae, cultured plants and
animal cell lines as well (Hirata et al., 2003). Boron containing
metabolite, Borophycin isolated from marine strains viz. Nostoc
linckia and N spongiaeforme var. tenue, and cryptophycin from
Nostoc sp. ATCC 53789 and GSV 224 has been found to exhibit
potent cytotoxicity against human tumor cell lines (Burja et al.,
2001).
Therefore, in the present study cyanobacterium Nostoc
sp. MGL001 isolated from fresh water body was used for
the screening of antibacterial bioactive compound. Various
chromatographic techniques like thin layer chromatography
(TLC) and high performance liquid chromatography (HPLC)
were performed for purification and purified compound were
then subjected to electrospray ionization mass spectrometry
(ESIMS) and nuclear magnetic resonance (NMR) spectroscopic
analysis for identification and structure elucidation. Additionally,
the design approaches mentioned above coupled with the in
silico computational toolkit for optimizing interactions between
ligand (bioactive compound) and receptor molecules. Here, 30S
ribosomal fragment (1YRJ, 1MWL, 1J7T, and 1LC4) (Vicens and
Westhof, 2001, 2002, 2003; Han et al., 2005) as well as OmpF
porin protein (4GCP, 4GCQ and 4GCS) (Ziervogel and Roux,
2013) was selected as target receptors for molecular docking with
ligand.
MATERIALS AND METHODS
Isolation and Identification of
Cyanobacterium
The experimental organism cyanobacterium Nostoc sp. MGL001
was collected from local fresh water pond (Kardmeshwar pond)
Chitaipur, Varanasi, India (25.2719◦ N, 82.9676◦ E). Pond has
an area 5012 m2 with the mean depth approximately 10.3 m.
This pond is present in vicinity of the adjacent temples and not
connected to any river.
Sample was washed several times with sterile water and
unialgal population of cyanobacterial strain was obtained by
serially diluting the source inocula and subsequently streaking
it on the solidified BG-11 agar medium. The purity of culture
was routinely checked by streaking cyanobacterial culture on
nutrient agar plates containing 0.5% of the glucose (w/v)
incubated for 24 h. This process was repeated multiple times
until pure micro-colonies were obtained. Further cyanobacterial
culture was grown in 500mL Erlenmeyer flasks containing BG11
medium (Rippka et al., 1979). The flasks were kept at 25 ± 2◦C
under white cool fluorescent light at an intensity of 95µmol
m−2 s−1, with a 14/10 h light/dark cycle. Identification of axenic
cyanobacterial strain was based on the morphological features
(Desikachary, 1959; Komarek, 2013) as well as 16S ribosomal
gene amplification (Nübel et al., 1997). The light microscope
(Dewinter) attached with a camera was used to study the
morphology of filaments and cells. The cell dimensions were
measured using software (Dewinter Biowizard 4.1).
To amplify the 16S ribosomal gene segment, DNA was
extracted from the exponentially grown cyanobacterial culture
growing on BG11 media using Himedia Bacterial DNA
purification kit (MB505). Concentration of DNA was measured
using Bio Spec Nano Spectrophotometer Life Science (Shimadzu
Biotech). Eluted DNA was stored in −20◦C. Amplification of
16S rDNA gene was performed using 16S rDNA bacteria specific
primers 27F forward (5′-AGAGTTTGATCCTGGCTCAG-3′)
and 1492R reverse (5′-TACGGTTACCTTGTTACGACTT-3′)
(Weisburg et al., 1991). The PCR amplification (BioRad, DNA
Engine, Peltier Thermal Cycler) of 16S rDNA was performed
using 25µl aliquots containing 20–50µg DNA template, 0.4µM
of each primers, 1.5µMMgCl2, 200µM dNTPs, and 1U/µl Taq
Polymerase. Program followed for PCR amplification was: initial
denaturation at 95◦C for 3min, 30 cycles of 30 s denaturation
at 94◦C, 40 s annealing at 55◦C, and 50 s extension at 72◦C
and final extension at 72◦C for 20min (Singh et al., 2015). The
amplified product was analyzed on a 1.2% agarose gel stained
with ethidium bromide in 1X TBE buffer and then visualized
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FIGURE 1 | Microphotographs of Nostoc sp. MGL001. (A) and (B) showing filament with vegetative cell (VC) and heterocysts (H).
FIGURE 2 | Neighbor-joining tree of Nostoc sp MGL001 with reference
strains using 16S rDNA gene sequences. Bootstrap values (%) are based
on 1000 replicates and shown at the branch point with more than 50%
bootstrap values.  Representing the cyanobacteriaum Nostoc sp. MGL001
used in the present study.
under gel documentation system. The obtained bands were
further cut down and eluted using Qiagen quick Gel Extraction
kit. The eluted amplified products were finally sent to Sci Genome
Cochin, Kerala, India for sequencing.
Nucleotide Sequence Analysis and
Construction of Phylogenetic Tree
The partial 16S rDNA sequence obtained from DNA
sequencing was then subjected to NCBI sequence database
FIGURE 3 | TLC pattern of methanolic crude extract from Nostoc sp.
MGL001 (A) using carbon tetrachloride and methanol (9:1) as mobile solvent.
(B) TLC pattern of 2nd TLC spot using ethyl acetate and hexane (1:1) as
mobile solvent.
viz. nucleotide basic local alignment search tool (Blastn)
(http://blast.ncbi.nlm.nih.gov/Blast.cgi) and aligned with the
already existing gene sequences of different cyanobacterial
species. Furthermore, the partial 16S rDNA sequence of the
experimental organism was submitted to the NCBI database
using the Sequin submission tool version 15.10. Evolutionary
history of closely related sequence in a BLAST search was
inferred by neighbor joining algorithm method for construction
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FIGURE 4 | HPLC chromatogram of the spot “E” fraction of the Nostoc sp. MGL001 crude extract obtained from TLC.
TABLE 1 | Antibacterial activity of the EMTAHDCA compound against gram negative bacteria.
Test organism Inhibition zone (mm) at different concentrations of EMTAHDCA (µg/mL)
100 150 200 250
E. coli 4.78± 0.324 11.15 ± 0.117 11.13± 0.123 11.15± 0.133
P. vulgaris 5.22± 0.221 10.17 ± 0.235 10.16± 0.353 10.16± 0.271
P. aeruginosa 4.11± 0.356 9.16 ± 0.211 9.15± 0.233 9.15± 0.279
of phylogenetic tree (Saitou and Nei, 1987). Evolutionary analysis
was performed using MEGA 6 software (Tamura et al., 2013).
Preparation of Crude Extract
For the preparation of crude extract 40–45 days old
cyanobacterial culture was used based on the method of
Doan et al. (2000). Cyanobacterial cells (10 g fresh weight)
were harvested by centrifugation at 10,000 rpm for 15min
(Remi, India) and then lyophilized (Christ-Alpha 1-2,
Germany). Lyophilized cyanobacterial biomass (5 g) was
extracted twice or thrice in 300 mL methanol (100%) by
keeping it on shaker (150 rpm for 48 h) and centrifuged
at 10,000 rpm (15min). Supernatant was evaporated to
dryness using rotary vacuum evaporator (Perfit, India) at
40◦C and redissolved in 5mL of 100% methanol for further
use.
Thin Layer Chromatography (TLC)
Dried crude extract of Nostoc sp. MGL001 was dissolved in
methanol and purified by TLC (TLC silica gel 60, Merck,
Darmstadt, Germany). In this process, carbon tetrachloride:
methanol (9:1) was used as the mobile phase and silica was
used as the stationary phase. The UV-illuminated orange
bands on the TLC plate were designated as A, B, C, D, E,
and F, which were dissolved separately in 100% methanol
(1mL). Further each elute was then subjected to TLC
purification using ethyl acetate: n-hexane (1:1). Only the potent
designated bands of the first step were subjected to the second
step.
Purification of the Antibacterial Compound
Produced by Nostoc sp. MGL001 by High
Performance Liquid Chromatography
(HPLC) Fractionation
Potent band elute after second step of TLC was dissolved in
HPLC grade methanol. Separation was achieved using HPLC
(Waters, USA) equipped photodiode array (PDA) detector and
inline degasser. The reverse phase Nova pack C18 Spherisorb
S10 ODS column (4.6 × 150mm, 5mm particle size) was used
and temperature maintained at 40◦C. Mobile phase consists
of Milli-Q water (A) and acetonitrile (B), containing 0.05%
trifluoroacetic acid. All solvents used in study were HPLC
grade and filtered through a 0.22µm membrane filter. For
mobile phase, linear gradient programme was: 0min 25%
B, 35min 70% B, 37min 70% B, 38min 25% B, 60min
25% B (Lawton et al., 1994). Flow rate of 1ml min−1 was
maintained for sample run and separation was monitored at
200–300 nm (Harada et al., 1999) having 1.2 nm resolution.
Empower2 software was used for instrumentation and data
acquisition.
Antibacterial Assay
Pure fraction of bioactive compound was collected through
HPLC and concentrated using rotary vacuum evaporator.
Concentrated solid mass of pure bioactive compound were
weigh. In order to perform antibacterial assay different
concentrations of pure bioactive compound were prepared viz.
100, 150, 200, and 250µg/mL in the volume of 1% methanol
separately. Antibacterial activity was tested by agar disc diffusion
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FIGURE 5 | 1H NMR spectrum of the bioactive compound (spot “E” eluate) derived from Nostoc sp. MGL001.
FIGURE 6 | 13C NMR spectrum of the bioactive compound (spot “E” eluate) derived from Nostoc sp. MGL001.
method using 5mm diameter filter paper discs. Agar was
inoculated with a standardized quantity of the suspension of
the test organisms. Known amount of pure bioactive compound
were loaded on filter paper discs. Control discs received only the
solvent (1% methanol). Discs were allowed to remain at room
temperature until complete solvent evaporation and then placed
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on the seeded agar plates. The diameter of the inhibition zone
(from periphery of disc to periphery of zone) was measured in
mm after 24 h incubation at 37◦C.
ESI-MS and NMR Studies
Electrospray ionization (ESI) equipped with time of flight mass
spectrometer were recorded on Bruker daltonics AmaZon SL.
Capillary voltage 3500 V in positive ion mode was set having
20µL/min flow rate. The 1H, H-H COSY, 13C{1H}, DEPT-
135, and DEPT-90 NMR spectra were recorded on a Bruker
AVANCE III HD-500 MHz multinuclear FTNMR spectrometer
at 25◦C.
Optimization of Isolated Bioactive
Compound and Docking Study
For visualization of isolated compound Discovery Studio 3.0 tool
was used (Gao and Huang, 2011).
TABLE 2 | NMR Spectral data of EMTAHDCA.
S. No. 1H/13C{1H}
(Multiplicity)
No. of proton Peak position (δ) Coupling
constant
3JH-H(Hz)
1 -COOH (s) 02 11.979 –
2 -N = CH (s) 01 8.935 –
3 -C10H (d) 01 7.899–7.872 13.50
4 -C1/4H(s) 02 7.635 –
5 -C11H(d) 01 7.141–7.127 7.0
6 -C6/7/14/15H (s) 04 7.010 –
7 -C1′H (q) 02 4.601–4.558 7.5/7.5
8 -C5′′H (s) 02 3.505 –
9 -C2′′H (t) 04 3.232–3.213 5.0
10 -C3′′H (t) 04 2.894–2.875 5.0
11 -C2′H (t) 03 1.425–1.396 7.0
12 -COOH – 176.08 –
13 -C22 – 166.05 –
14 -C12 – 153.84 –
15 -C19/26/21/24 – 151.86 –
16 -C27 – 148.31 –
17 -C23 – 146.00 –
18 -C17/18 – 145.92 –
19 -C1/4 – 137.20 –
20 -C2/3 – 135.05 –
21 -C9 – 118.96 –
22 -C10 – 111.14 –
23 -C6/7/14/15 – 110.96 –
24 -C20/25 – 107.02 –
25 -C11 – 105.43 –
26 -C5′′ – 69.73 –
27 -C2′′ – 50.78 –
28 -C3′′ – 48.95 –
29 -C1′ – 45.34 –
30 -C2′ – 14.22 –
s, singlet; q, quartet; d, doublet; t, triplet.
Selection of Target Structures
The small ribosomal subunit (30S) fragment and protein
structures were selected for interaction with isolated bioactive
compound (ligand). The 3-D crystal structure of the target viz.
the RNA fragments (1YRJ, 1MWL, 1J7T, and 1LC4) (Vicens
and Westhof, 2001, 2002, 2003; Han et al., 2005) and OmpF
porin structures (4GCP, 4GCQ, and 4GCS) (Ziervogel and
Roux, 2013) were retrieved from the protein databank (PDB)
(www.rcsb.org/pdb) and further used for interaction calculation
using YASARA software (Krieger and Vriend, 2014). Active
site of the targeted protein was predicted using MetaPocket
2.0 (http://projects.biotec.tu-dresden.de/metapocket/) (Huang,
2009; Zhang et al., 2011).
Receptor Preparation and Docking
The complexes of RNA fragments and porin protein with
heteroatom, water molecules and ligands were taken for
receptor preparation. The heteroatom, water molecules and
ligands were removed using Discovery Studio 3.1 before
docking. The Docking calculation was performed for RNA
fragments and porin protein with ligand (bioactive compound).
The target protein was set in YASARA to run macro file
(dock_run.mcr). The YASARA structure provides Autodock
and VINA tools to dock ligands with proteins at the
touch of a button (Morris et al., 1998; Trott and Olson,
2010).
RESULTS
Isolation and Identification
The morphological study of the cyanobacterium Nostoc sp.
MGL001 showed that it contains squarish to cylindrical
vegetative cells (Figure 1). Nostoc sp. MGL001 (GenBank,
accession no. KX721474) and other close homologs for the
cyanobacterium can be found from the alignment view tree
(Figure 2).
FIGURE 7 | Proposed structure of bioactive compound was
9-Ethyliminomethyl-12-(morpholin - 4 - ylmethoxy) - 5, 8, 13, 16 -
tetraaza - hexacene - 2, 3 dicarboxylicacid (EMTAHDCA).
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FIGURE 8 | In silico interaction between selected ligand (EMTAHDCA) and target RNA fragment (A) 1YRJ (B) 1MWL, (C) 1J7T, (D) 1LC4.
FIGURE 9 | In silico interaction between selected ligand (EMTAHDCA) and target OmpF porin protein (4GCP). (A) Poses of docked complexes, green color
in sphere indicates prominent active site where the ligand interacted, (B) 2D level interaction, (C) 3D level interaction.
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FIGURE 10 | In silico interaction between selected ligand (EMTAHDCA) and target OmpF porin protein (4GCQ). (A) Poses of docked complexes, green
color in sphere indicates prominent active site where the ligand interacted, (B) 2D level interaction, (C) 3D level interaction.
FIGURE 11 | In silico interaction between selected ligand (EMTAHDCA) and target OmpF porin protein (4GCS). (A) Poses of docked complexes, green
color in sphere indicates prominent active site where the ligand interacted, (B) 2D level interaction, (C) 3D level interaction.
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TLC and HPLC Analysis
Thin layer chromatography (TLC) of the crude extract of
cyanobacterium produced five bands A, B, C, D, E, and F
(Figure 3). Only band E showed potent antibacterial property.
Further band E was purified by HPLC, the individual peak with
retention time (Rt) of 1.40min (Figure 4) were collected.
Antibacterial Bioassay
This purified compound shows extensive antimicrobial activity
against various gram negative bacterial strains chosen, such
as Escherichia coli (KX758560), Proteus vulgaris (KX758561),
and Pseudomonas aeruginosa (KX758562). Maximum zone of
inhibition at a concentration of 150 µg/mL of pure compound
isolated from Nostoc sp. MGL001 was observed viz. 11.15 ±
0.117, 10.17 ± 0.235, and 9.16 ± 0.211mm against Escherichia
coli, Proteus vulgaris and Pseudomonas aeruginosa, respectively
(Table 1). Upon further increasing the concentration upto
250µg/mL, no further increase in the size of zone was observed.
ESI and NMR
The obtained whitish powder compound was used for the
analysis through ESI and NMR. The 1H NMR (500.30
MHz;) δ ppm w.r.t. DMSO-d6(2.500) (Figure 5) and
13C{1H}
NMR (125.80 MHz) δ ppm w.r.t. DMSO-d6(39.51) (Figure 6)
in DMSO-d6 at 25
◦C spectral data are given in Table 2.
Therefore, on the basis of NMR, proposed structure of
bioactive compound was 9-Ethyliminomethyl-12-(morpholin - 4
- ylmethoxy) -5, 8, 13, 16–tetraaza–hexacene - 2, 3- dicarboxylic
acid (EMTAHDCA) (Figure 7). High resolution ESI-MS was
operated in positive ion mode revealed an m/z at 591.02
(M+H+) corresponding to the molecular formula C32H26N6O6
(Molecular weight-590.59) assigned in full agreement with NMR
spectral data.
Molecular Docking
Molecular docking was successfully performed between selected
ligand (EMTAHDCA) and target receptor RNA fragments
(PDB ID: 1YRJ, 1MWL, 1J7T, and 1LC4) (Figure 8) and
TABLE 3 | Prominent active site residues identification of selected Omp
porin protein models (4GCP, 4GCQ, and 4GCS).
S.No. Target PDB
ID
Common active site 1 residues
1. OmpF porin
protein
4GCP Arg42, Arg82, Tyr32, Leu291, Val292, Asn293,
Tyr294, Asn316, Ile318, Val326, Asp121,
Gly327, Tyr124, Pro239, Ile240, Thr241,
Phe118, Gly119, Gly120, Arg167, Glu117,
Ala123, Asp113, Arg132
2. 4GCQ Lys16, Arg82, Pro116, Tyr302, Thr300,
Leu115, Tyr102, Asp113, Met114, Arg270,
Tyr106, Gln262, Glu62, Leu83, Gly110,
Asp107, Tyr111, Arg140, Lys219, Glu181,
Ser179, Val188, Asn152, Ser177
3. 4GCS Lys89, Ser95, Arg140, Tyr58, Asp97, Asp107,
Phe85, Asn101, Gln60, Tyr106, Lys46, Tyr102,
Gly110, Tyr14, Lys16, Phe340, Gln339, Gly15
OmpF porin protein (4GCP, 4GCQ, and 4GCS) (Figures 9,
10, 11) using YASARA software. The active site of OmpF was
determined using Metapocket and results are represented in
Table 3. Summary of molecular docking results of selected
ligand with drug target RNA fragment and OmpF porin
protein are represented in Table 4. The binding energy
was found to be 000011.1450, 000010.0550, 000009.8620,
and 000009.9690 for 1YRJ, 1MWL, 1J7T, and 1LC4 RNA
fragments, respectively. Dissociation constant [pM] was
found to be 00000000006770.2808, 00000000042617.4336,
00000000059028.0117, and 00000000059028.0117 for 1YRJ,
1MWL, 1J7T, and 1LC4 RNA fragments, respectively (Table 4).
Contacting receptor residues were identified through YASARA
software and found that GA5, UA6, AA8, AA10, AB33, GB39, and
UA15 were common active site residues between reported 1YRJ
complex with Apramycin and selected ligand.
In case of 1MWL RNA fragment bases CA10, CA11, GA12,
GA13, UA14, C A20, GB26, UB27, CB28, CB30, AB31, CB32, CB33, and
GB34 were involved in interaction between ligand and 1MWL
RNA fragment, in which GB26, UB27, CB28, and CB30 bases
were common active site residues between reported Geneticin
antibiotic complex (1MWL) and ligand.
The ligand and 1J7T RNA fragment interacted with the
following binding residues CA10, CA11, GA12, GA13, UA14, GA18,
UA19, CA20, CB25, GB26, UB27, CB28, AB29, CB30, AB31, CB32, CB33,
and GB34 in which GA18, UA19, GB26, UB27, CB28, AB29, and CB30
bases were common between reported paromomycin antibiotic
complex (1J7T) and ligand (Table 4).
Active site residues viz. UA15, GA16, AA17, AA18, GA19, UA20,
CA21, CB27, GB28, UB29, CB30, AB31, CB32, AB33, and CB34 were
involved in interaction with 1LC4 RNA fragment and ligand in
which GA16, AA18, GA19, UA20, CB27, GB28, CB30, and AB31 bases
were common binding residues between reported tobramycin
antibiotic complex (1LC4) and ligand.
In case of 4GCP porin protein docking results, site 1 residues
Tyr32, Arg42, Arg82, Asp113, Glu117, Phe118, Gly119, Gly120,
Asp121, Ala123, Tyr124, Arg132, Arg167, Pro239, Ile240, Thr241,
Leu291, Val292, Asn293, Tyr294, Asn316, Ile318, Val326, and Gly327
were involved in interaction with good positive energies and
dissociation constant. The site 1 is the major prominent site
for interaction of any compound. The residues of site 1 (Tyr32,
Phe118, Gly119, Gly120, Asp121, Tyr124, Leu291, Val292, Asn316, and
Val326) are common to the reported active site known against
ampicillin antibiotics (Figure 9, Table 4). The 2D and 3D view
of interacted residues also mentioned in Figure 9. In residue
interaction electrostatic bond, van der waals, covalent bond and
hydrogen bond were involved.
Molecular docking between 4GCQ porin protein and ligand
indicates that active site 1 residues Lys16, Glu62, Arg82, Leu83,
Tyr102, Tyr106, Asp107, Gly110, Tyr111, Asp113, Met114, Leu115,
Pro116, Glu181, Val188, Lys219, Gln262, Arg270, Thr300, and Tyr302
were involved in interaction, whereas only Arg82 are common to
the reported active site known against Carbenicillin antibiotics
(Figure 10, Table 4). The electrostatic bond, van der waals,
covalent bond and hydrogen bond were involved in residues
interaction could be clearly visible in 2D and 3D view in
Figure 10.
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TABLE 4 | Summary of molecular docking results of selected ligand with drug target RNA fragment and OmpF porin protein.
S.No. Ligand Target PDB
ID
Binding
energy
[kcal/mol]
Dissociation
constant [pM]
Contacting
receptor residues
Reported active site
residues
Common
1. EMTAHDCA RNA
Fragment
1YRJ 000011.1450 00000000006770.2808 GA5, UA6, CA7, AA8,
AA10, CA11, CA12,
GA13, UA15, AB33,
CB34, CB35, GB37,
UB38, GB39
CA4, GA5, UA6, AA8,
AA10, UA15, CA4, GA5,
UA6, AA8, AA10, UA15,
GA16, AA17, AA18,
GA19, UA20, UB25,
AB31, CB32, AB33,
GB39, AB40, AB41
GA5, UA6,
AB33, GB39,
AA8, AA10,
UA1, UA15,
AB33, GB39
2. EMTAHDCA RNA
Fragment
1MWL 000010.0550 00000000042617.4336 CA10, CA11, GA12,
GA13, UA14, CA20,
GB26, UB27, CB28,
CB30, AB31, CB32,
CB33, GB34
AB33, GB39, GA4, UA5,
AA6, CA7, CA7, CA8,
GA15, AA16, AA17,
GA18, UA19, CB25,
GB26, UB27, CB28,
AB29, CB30, GB37,
AB38, AB39, GB40,
UB41
GB26, UB27,
CB28, CB30
3. EMTAHDCA RNA
Fragment
1J7T 000009.8620 00000000059028.0117 CA10, CA11, GA12,
GA13, UA14, GA18,
UA19, CA20, CB25,
GB26, UB27, CB28,
AB29, CB30, AB31,
CB32, CB33, GB34
GA4, UA5, CA6, AA7,
UA17, GA15, AA16,
AA17, GA18, UA19,
GB26, UB27, CB28,
AB29, CB30, UB36,
GB37, AB38, AB39,
GB40
GA18, UA19
4. EMTAHDCA RNA
Fragment
1LC4 000009.9690 00000000049274.9414 UA15, GA16, AA17,
AA18, GA19, UA20,
CA21, CB27, GB28,
UB29, CB30, AB31,
CB32, AB33, CB34
CA4, GA5, CA7, GA16,
AA18, GA19, UA20,
CB27, GB28, CB30,
AB31, GB39, AB41,
GB42, UB43
GA16, AA18,
GA19, UA20,
CB27, GB28,
CB30, AB31
5. EMTAHDCA OmpF Porin
protein
4GCP 000009.8890 00000000056398.4141 Tyr32, Arg42, Arg82,
Asp113, Glu117,
Phe118, Gly119,
Gly120, Asp121,
Ala123, Tyr124,
Arg132, Arg167,
Pro239, Ile240,
Thr241, Leu291,
Val292, Asn293,
Tyr294, Asn316,
Ile318, Val326, Gly327
Ser31, Tyr32, Gly33,
Phe118, Gly119, Gly120,
Asp121, Tyr124, Lys243,
Leu291, Val292, Asn316,
Val326, Gly327
Tyr32, Phe118,
Gly119, Gly120,
Asp121, Tyr124,
Leu291, Val292,
Asn316, Val326,
Gly327
6. EMTAHDCA OmpF porin
protein
4GCQ 000009.9500 00000000050880.7266 Lys16, Glu62, Arg82,
Leu83, Tyr102,
Tyr106, Asp107,
Gly110, Tyr111,
Asp113, Met114,
Leu115, Pro116,
Glu181, Val188,
Lys219, Gln262,
Arg270, Thr300,
Tyr302
Tyr22, Tyr32, Gly33,
Arg42, Arg82, Glu117,
Phe118, Gly119, Gly120,
Asp121 Arg132, Val 292
Arg82
7. EMTAHDCA OmpF porin
protein
4GCS 000008.6880 00000000428165.4063 Tyr14, Gly15, Lys16,
Lys46, Tyr58, Gln60,
Phe85, Lys89, Ser95,
Asp97, Asn101,
Tyr102, Tyr106,
Asp107, Gly110,
Arg140, Gln339,
Phe340
Thr165, Arg168, Ser248
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Active site 1 residues involved in interaction were Phe85, Ser95,
Asn101, Tyr102, Tyr106, Gly110, and Arg140 in case of 4GCS porin
protein and ligand docking through van der waals bonding,
Residues like Tyr14, Lys16, Gly15, Phe34, Gly15, Gln339, Asp97,
Lys46, Lys89, Tyr58, Asn101, and Asp107 involved in electrostatic
bonding whereas Arg82 involved in hydrogen bond interaction
(Figure 11, Table 4).
DISCUSSION
Cyanobacteria are known to produce a wide variety of
biologically active compounds. To the best of our knowledge,
this type of new bioactive compound EMTAHDCA is first time
reported from fresh water cyanobacterium Nostoc sp. MGL001.
In order to isolate EMTAHDCA various chromatographic
techniques were tested but TLC was found to be most useful
tool to achieve the separation of complex mixtures of organic
molecules. Competition between solute and the mobile phase
is responsible for the separation of compounds through TLC
(Kumar et al., 2013). In order to separate unknown bioactive
compounds, different gradients of solvents were tested and
ultimately carbon tetrachloride: methanol in 9:1 ratio was found
to be best for separation point of view. Same solvent composition
was also used by Srivastava et al. (2015) to separate bioactive
compound from fresh water cyanobacteria Geitlerinema sp.
CCC728 and Arthrospira sp. CCC729.
Liquid chromatography is one of the most efficient and
powerful separation methods for the preparative purification
and isolation of biological substances (Nikitas and Pappa-Louisi,
2009). A number of different chromatographic methods were
considered for purification of bioactive compounds but reason
behind selection of HPLC technique was its reproducibility,
sensitivity, high resolution, and absence of extensive sample
preparation or derivatization (Quilliam, 2003; Snyder and Dolan,
2006). Water is the weakest eluent for reverse phase HPLC
so; its eluent strength is then modified by adding methanol
or acetonitrile which are less polar but miscible solvents. After
testing methanol and acetonitrile based systems acetonitrile was
selected as mobile phase because it gave better peak shapes, stable
baselines and sharper resolution as compared to methanol.
The use of ESI-MS systems when coupled with a HPLC-
system increases their selectivity and benefits from both
techniques (Vishwakarma and Rai, 2013). For the structure
elucidation of newly isolated compounds NMR methods
have been used as it is very much capable of elucidating
intact biomaterials nondestructively without any preceding
derivatization (Willmann et al., 2011). Due to the simplicity of
sample preparation and ease of interpretation of characteristic
signals, NMR was favored as natural products are closely related
and difficult to separate. The 1H and 13C{1H} NMR spectral data
of EMTAHDCA has already been presented and interpreted in
result section. The proton NMR spectrum of the EMTAHDCA
(Figure 5), as per the structure, is expected to show a broad
peak at δ 11.979 (due to presence two acidic proton of –COOH
groups), two doublet [at δ 7.899–7.872 (due to presence of one
aromatic proton, such as C10H) and at δ 7.141–7.127 (due to
presence of one aromatic proton, such as C11H)], four singlet
[at δ 8.935 (due to presence of one proton –N = CH group), δ
FIGURE 12 | H-H COSY NMR spectrum of EMTAHDCA.
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7.635 (due to presence of two aromatic protons, such as C1H
and C4H), δ 7.010 (due to presence of four aromatic protons,
such as C6H, C7H, C14H, and C15H) and at δ 3.505 (due to
presence of two protons of methylene group, such as C5′′H)],
one quartet at δ 4.601–4.558 (due to presence of two protons
of methylene group, such as C1′H) and three triplets [at δ
3.232–3.213(due to presence of two protons of methylene group,
such as C2′′H), δ 2.894–2.875(due to presence of two proton
of methylene group, such as C3′′H) and at δ 1.425–1.396 (due
to presence of three protons of methyl group, such as C2′H)].
The splitting pattern of different type of protons of aliphatic
region also confirmed by H-H COSY spectrum (Figure 12),
in this spectrum the methylene group protons (C1′H) coupled
with the methyl group protons (C2′H) and other methylene
group protons (C2′H) coupled with another methylene group
protons (C3′H). In the
13C{1H} NMR spectrum (Figure 6), 19
carbon signals were observed, including carbonyl carbon (δ
176.08), one imine carbon (δ 148.31), four aromatic carbons
(δ 137.20, 111.14, 110.96, and 105.43), eight different type
quaternary aromatic carbons (δ 166.05, 153.84, 151.86, 146.00,
145.92, 135.05, 118.96, and 107.02), four different type methylene
carbons (δ 69.73, 50.78, 48.95, and 45.34), and one methyl carbon
(δ 14.22). The different type of carbon interpreted with help of
DEPT-90 and DEPT-135 NMR spectral technique, in DEPT-135
spectrum (Figure 13), carbon with one hydrogen (four type
aromatic carbons and one imine carbon) and three hydrogens
(one methyl carbon) shows positive peak, whereas carbon
has two hydrogens (four different type of methylene carbons)
shows negative peak and in DEPT-90 spectrum (Figure 14),
carbon with one hydrogen (four type aromatic carbons and
one imine carbon) shows only positive peak. The spectrum
consists of all the expected signals as shown in spectral data of
NMR section. The predicted structure of EMTAHDCA using
ESI-MS and NMR spectra were verified by subjecting predicted
structure on Pubchem (https://pubchem.ncbi.nlm.nih.gov/)
and PubMed NCBI https://www.ncbi.nlm.nih.gov/pubmed)
and by comparing experimental data with published literature
on bioactive compounds of cyanobacteria but structure of
EMTAHDCA clearly indicated that it is a novel compound that
was not reported earlier in any literature or natural product
database.
The ESI-MS and NMR spectra were verified by comparing
experimental data with published literature on bioactive
compounds but structure of EMTAHDCA clearly indicated that
it is a novel compound that was not reported in literature or
natural product database.
Also EMTAHDCA identified as an antibacterial agent
through in vitro and in silico approaches. The present work
based on in silico preclinical evaluation of novel isolated
compound EMTAHDCA to proceed ahead for further drug
trials. Structure elucidation of bioactive compound EMTAHDCA
(Ethyliminomethyl-12-(morpholin - 4 - ylmethoxy) -5, 8, 13, 16 -
tetraaza - hexacene - 2, 3 dicarboxylic acid) was done through
NMR already mentioned in results section. This compound
contain morpholin moiety that is rare in nature. The 2-
hydroxymorpholine moiety was also observed in bacilosarcins
A isolated from marine-derived bacterium Bacillus subtilis TP-
B0611 showed growth inhibition against barnyard millet (Azumi
FIGURE 13 | DEPT-135 NMR spectrum of EMTAHDCA.
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FIGURE 14 | DEPT-90 NMR spectrum of EMTAHDCA.
et al., 2008). Morpholin is commonly used in organic synthesis.
It acts as a building block in the preparation of the anticancer
agent gefitinib (Iressa), the antibiotic linezolid and the analgesic
dextromoramide (Fung et al., 2001; McKillop et al., 2005).
Presence of morpholin moiety in the bioactive compound
EMTAHDCA is likely to be responsible for its antibiotic activity.
Pure bioactive compound EMTAHDCA (150µg/mL) possessed
antibacterial activity against gram negative bacterial strains
viz. E. coli, P. vulgaris, and P. aeruginosa. These strains were
tested in laboratory and found multi drug resistant (MDR) to
erythromycin, imipenem, ciprofloxacin and vancomycin (data
not shown). Bacterial adaptation to antibiotics generated serious
medical problem (Chalasani et al., 2015). This finding gives
an idea that EMTAHDCA compound could be used as an
alternative antibiotic against such resistant bacterial strains.
In order to prove its antibiotic potential in silico technique
was performed to know the interaction of selected bioactive
compound EMTAHDCA with small ribosomal subunit (30S)
(PDBID: 1YRJ, 1MWL, 1J7T, and 1LC4) fragment and OmpF
porin protein (PDBID: 4GCP, 4GCQ, and 4GCS).
Protein synthesis is a fundamental process performed by
ribosome. More than half of the total number of clinically
used antibiotics exerts their antibiotic effects on the bacterial
ribosomes by binding to several sites of 30 and 50S subunits
ultimately blocking protein synthesis (Franceschi and Duffy,
2006). Both the 30S and the 50S ribosomal subunits provide
functionally relevant active site pockets considered as
ribofunctional loci where antibiotics do act (Wilson, 2014).
The ribosomes are highly conserved organelles having precise
conformational variation which facilitates drug selectivity for
clinical use (Hermann, 2005).
The outer membrane (OM), unique to gram negative bacteria
acts as selective barrier by providing an extra protective
layer against a harsh environment. OM provides passage
for nonspecific charged and zwitterionic nutrient molecules
(Delcour, 2009). Three major general diffusion porins found in
E.coli are OmpF, OmpC, and PhoE. In several reports, loss of
OmpF, and OmpC porins are linked to antibiotic resistance,
especially for Escherichia coli and Salmonella typhimurium
(Nikaido, 2003). Therefore, a better understanding of how
modification of membrane permeability triggers bacterial
resistance to antibiotics is necessary for the development of new
antibiotic therapy strategies.
Molecular docking calculation between EMTAHDCA and
target receptor molecule (RNA fragment) showed good binding
affinity with best positive energies for selected compound
EMTAHDCA.More positive energies indicates stronger binding,
and negative energies mean no binding (Krieger and Vriend,
2014). Bases involved in interaction between ligand and
ribosomal fragment resides at the prominent active site of
ribosomal fragment. Similar type of interaction was observed
in the case of EMTAHDCA docking with OmpF porin protein.
The crystal structures of OmpF in complex with ampicillin,
carbenicillin and ertapenem (4GCP, 4GCQ, and 4GCS) have
been already reported. Residues involved in interaction between
selected ligand andOmpF porin proteins was found in prominent
active site (site 1) predicted by Metapocket. Therefore, with the
help of emerging molecular docking tools, we could able to prove
that isolated compound EMTAHDCA have ability to work as
an antibiotic agent and also recognize their precise mode of
action against targeted host. This study suggested that selected
compound EMTAHDCA could better act in comparison with
reported antibiotics and able to serve as clinical candidate.
CONCLUSION
Novel bioactive compound EMTAHDCA isolated from Nostoc
sp. MGL001 has antibacterial activity against multi drug resistant
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bacterial strains viz. E coli, P vulgaris, and P aeruginosa through
in vitro and in silico studies. Therefore, it is worth mentioning
that EMTAHDCA could serve as potential antibiotic drug.
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